We report a new neutral hemoglobin (Hb) variant, found, during neonatal screening, in a child originating from Afghanistan. This variant was revealed by cation exchange and reversed phase high performance liquid chromatography (HPLC), but was silent in electrophoretic methods except for globin chain electrophoresis in the presence of urea and Triton X-100. The structural modification was determined by protein structure studies and the substitution established by tandem mass spectrometry (MS/MS). The mutation, located near to the 2,3-diphos phoglycerate (2,3-DPG) binding site, was without any hematological consequences. The pitfalls presented by the presence of neutral Hb variants as modulator factors of the main hemoglobinopathies is discussed.
INTRODUCTION

MATERIALS AND METHODS
In this program the samples were collected from a heelprick onto filter paper when the child was 7-10 days old. A dried blood spot of 0.3 cm diameter was obtained from which Hb was eluted to be analyzed by isoelectric focusing (IEF) and by cation exchange high performance liquid chromatography (HPLC) (VARIANT I; Bio-Rad Laboratories, Hercules, CA, USA). When an abnormal Hb is observed in a baby, venous blood from his parents is collected into EDTA vacutainers for further analysis.
Hematological parameters were obtained by routine methods (Coulter STKS; Beckman Coulter, Miami, FL, USA). Electrophoretic and chromatographic studies were done as previously described [4] . Procedures for separa tion of globin chains, aminoethylation, and digestion with trypsin are detailed elsewhere [4] . Electrospray mass spectrometry (ES-MS) studies on the globin and by tandem mass spectrometry (MS/MS) on the peptides were done as previously described [4] .
RESULTS
An abnormal Hb was found during a neonatal screen ing in a child, and later in his 33-year-old father, both from Afghanistan. The father's red blood cell parameters were: RBC 5.41 x 10 12 /L, Hb 14.9 g/dL, MCV 82.2 fL, MCH 27.5 pg. The variant, amounting to 37.5% of the total Hb, was observed eluting between Hb A and Hb A 2 at 2.96 min. by cation exchange HPLC, using the β-Thalassemia Short Program (Bio-Rad Laboratories) (Fig. 1) . It was not separated from Hb A by IEF or by any other electropho retic methods except for globin chain electrophoresis in the presence of urea and Triton X-100 where it was slight ly more hydrophobic than normal (21.5 in an arbitrary scale where normal α-globin migrates at 10.0 and β at 20.0). This increased hydrophobicity of the β chain was confirmed by analytical reversed phase HPLC globin showed an abnormal β chain with a mass increased by 49 ± 1Da as compared to normal, which could correspond to Val→Phe, Asp→Tyr or Asn→Tyr.
Globin was prepared from the total hemolysate and the chains were separated by reversed phase HPLC. Since the two β chains could not be separated at the preparative level, a mixture containing the normal and abnormal β chains was aminoethylated, digested with trypsin and ana lyzed by reversed phase HPLC. The elution pattern of the tryptic peptides showed that there was an abnormal βT-9 peptide that eluted after the normal one (Fig. 3) . Tandem mass spectrometry analysis of this peptide and of the un cleaved βT-8,9, both of which displayed a 49 Da mass increase compared to the normal, showed that the mass difference started at ion Y3 (…Asn-Leu-Lys), for which the value was 423 Da instead of 374Da. The structural change was therefore located at position 80 where the usual asparagine was replaced by a tyrosine (Fig. 4) . This variant has been named Hb Hounslow for the place where the proband lives. According to the HUGO nomenclature, this amino acid exchange should correspond, at the DNA level, to the HBB: c.241A→T mutation. [6] . Many of the neutral variants described are clinically silent or have minimal hematolog ical consequences in the heterozygous state but some inter act with a thalassemia trait, resulting in a thalassemia intermedia phenotype or with a sickle cell trait and favor sickling. When screening for a specific abnormality, such as Hb S or a thalassemic phenotype, one method may be sufficient to reveal the defect, but it is important to be aware that another silent abnormality may coexist and act as a gene modifier. Thus, phenotype screening should include at least two methods that explore different proper ties in order not to miss a neutral variant. Additional techniques such as reversed phase HPLC and ES-MS may show the presence of a neutral variant when a combination of IEF and cation exchange HPLC fail to reveal it, while hematological arguments would suggest its presence. For example, these two last techniques were required for detecting Hb Zoetermeer [α21(B2)Ala→Ser] [7] .
DISCUSSION
Residue EF4, which is modified in Hb Hounslow, is located externally near to the 2,3-DPG binding pocket. A comparison of more than 1,100 sequences of molecules from the globin family (Hbs, myoglobins, cytoglobins and neuroglobins from various species) showed that this posi tion is mostly occupied by an aspartic acid (35%) or an asparagine (30%) and means that conservation of the size of this residue and a possibility for hydrophilic interaction may be important in evolution [8] . Hb G-Szuhu (Asn→ Lys), also clinically silent, is the other β chain variant that involves position EF4 [9] . 
